Angela Vincent

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8328013/publications.pdf

Version: 2024-02-01

695	53,905	997 114	1980 206
papers	citations	h-index	g-index

800	800	800	22699
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neuroimmune disorders in COVID-19. Journal of Neurology, 2022, 269, 2827-2839.	3.6	27
2	Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective. Frontiers in Immunology, 2022, 13, 833548.	4.8	7
3	Slow Channel Syndrome Revisited: 40 Years Clinical Follow-Up and Genetic Characterization of Two Cases. Journal of Neuromuscular Diseases, 2022, , 1-8.	2.6	0
4	Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 995-1000.	1.9	19
5	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	7.9	16
6	Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice. Neuropathology and Applied Neurobiology, 2021, 47, 316-327.	3.2	9
7	Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. Biological Psychiatry, 2021, 90, 9-15.	1.3	14
8	Autoantibodies in Japanese patients with ocular myasthenia gravis. Muscle and Nerve, 2021, 63, 262-267.	2.2	8
9	Neuronal surface antibodies are common in children with narcolepsy and active movement disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 111-112.	1.9	2
10	Comparison of N-methyl-d-aspartate receptor antibody assays using live or fixed substrates. Journal of Neurology, 2021, 268, 1818-1826.	3.6	9
11	Multimodal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy. Annals of Neurology, 2021, 89, 753-768.	5.3	21
12	Systemic and cerebrospinal fluid immune and complement activation in Ugandan children and adolescents with longâ€standing nodding syndrome: A caseâ€control study. Epilepsia Open, 2021, 6, 297-309.	2.4	10
13	Using AChR antibody titres to predict treatment responses in myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 915-915.	1.9	2
14	Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	7
15	Antibodies to neuronal surface antigens in patients with a clinical diagnosis of neurodegenerative disorder. Brain, Behavior, and Immunity, 2021, 96, 106-112.	4.1	16
16	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 722237.	2.4	8
17	Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis. Communications Biology, 2021, 4, 1106.	4.4	20
18	The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110664.	1.0	4

#	Article	IF	Citations
19	Myasthenia Gravis and Related Disorders. , 2020, , 1011-1033.		1
20	Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry,the, 2020, 7, 93-108.	7.4	252
21	Paediatric myasthenia gravis: Prognostic factors for drug free remission. Neuromuscular Disorders, 2020, 30, 120-127.	0.6	18
22	SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	11
23	The Structure, Function, and Physiology of the Fetal and Adult Acetylcholine Receptor in Muscle. Frontiers in Molecular Neuroscience, 2020, 13, 581097.	2.9	41
24	Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment. Frontiers in Molecular Neuroscience, 2020, 13, 159.	2.9	23
25	Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30649-30660.	7.1	33
26	The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis. Frontiers in Molecular Neuroscience, 2020, 13, 610964.	2.9	83
27	Autoantibodies to the N-Methyl-D-Aspartate Receptor in Adolescents With Early Onset Psychosis and Healthy Controls. Frontiers in Psychiatry, 2020, 11, 666.	2.6	7
28	Neuronal antibody prevalence in children with seizures under 3 years. Neurology, 2020, 95, e1590-e1598.	1.1	9
29	Maternal-Autoantibody-Related (MAR) Autism: Identifying Neuronal Antigens and Approaching Prospects for Intervention. Journal of Clinical Medicine, 2020, 9, 2564.	2.4	10
30	Maternal Immunity in Autism Spectrum Disorders: Questions of Causality, Validity, and Specificity. Journal of Clinical Medicine, 2020, 9, 2590.	2.4	13
31	Disentangling etiologies of CNS infections in Singapore using multiple correspondence analysis and random forest. Scientific Reports, 2020, 10, 18219.	3.3	6
32	Standing on the shoulders of giants: 100 years of neurology and epidemic infections. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1129-1131.	1.9	3
33	Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 526-532.	1.9	11
34	Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophrenia Research, 2020, 222, 455-461.	2.0	17
35	ANTIBODIES AND RECEPTORS: From Neuromuscular Junction to Central Nervous System. Neuroscience, 2020, 439, 48-61.	2.3	20
36	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, 537.	2.4	27

#	Article	IF	Citations
37	The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain, 2020, 143, 3104-3120.	7.6	880
38	Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology, 2020, 95, e755-e766.	1.1	17
39	Autoimmune psychosis â€“ Authors' reply. Lancet Psychiatry,the, 2020, 7, 123-125.	7.4	3
40	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	3.6	17
41	Case report: Headache and neurological deficits with CSF lymphocytosis (HaNDL) associated with P/Q type voltage-gated calcium channel antibodies (CACNA1A). Cephalalgia, 2020, 40, 1003-1007.	3.9	6
42	Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain, 2019, 142, 2303-2318.	7.6	248
43	Autoimmune Encephalitis. , 2019, , 21-43.		0
44	Glycine receptor autoantibodies disrupt inhibitory neurotransmission. Brain, 2019, 142, 3398-3410.	7.6	47
45	AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Frontiers in Neurology, 2019, 10, 1028.	2.4	56
46	O10.3. EXPOSURE TO COMMON INFECTIOUS PATHOGENS IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS: CLINICAL AND IMMUNOBIOLOGICAL ASSOCIATIONS. Schizophrenia Bulletin, 2019, 45, S190-S191.	4.3	0
47	Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. Brain, Behavior, and Immunity, 2019, 81, 665-669.	4.1	15
48	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
49	Rapsyn facilitates recovery from desensitization in fetal and adult acetylcholine receptors expressed in a muscle cell line. Journal of Physiology, 2019, 597, 3713-3725.	2.9	13
50	Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1021-1026.	1.9	49
51	A Prospective Study of the Incidence of Myasthenia Gravis in the East Midlands of England. Neuroepidemiology, 2019, 53, 93-99.	2.3	24
52	Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodies. Brain, 2019, 142, 2000-2012.	7.6	35
53	Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clinical Therapeutics, 2019, 41, 836-847.	2.5	10
54	Doxycycline for the treatment of nodding syndrome (DONS); the study protocol of a phase II randomised controlled trial. BMC Neurology, 2019, 19, 35.	1.8	14

#	Article	IF	Citations
55	False-positive acetylcholine receptor antibody results in patients without myasthenia gravis. Journal of Neuroimmunology, 2019, 332, 69-72.	2.3	14
56	In vitro neuronal network activity as a new functional diagnostic system to detect effects of Cerebrospinal fluid from autoimmune encephalitis patients. Scientific Reports, 2019, 9, 5591.	3.3	9
57	Acquired neuromyotonia in children with <scp>CASPR</scp>2 and <scp>LGI</scp>1 antibodies. Developmental Medicine and Child Neurology, 2019, 61, 1344-1347.	2.1	16
58	Acquired neuromyotonia in thymomaâ€associated myasthenia gravis: a clinical and serological study. European Journal of Neurology, 2019, 26, 992-999.	3.3	17
59	GP230â€...Fetal acetylcholine receptor inactivation due to maternal myasthenia gravis: an underrecognised, devastating but potentially preventable and treatable disorder. , 2019, , .		0
60	John Newsom-Davis. 18 October 1932â€”24 August 2007. Biographical Memoirs of Fellows of the Royal Society, 2019, 67, 327-355.	0.1	1
61	Muscle acetylcholine receptor conversion into chloride conductance at positive potentials by a single mutation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21228-21235.	7.1	4
62	In vivo Mechanisms of Antibody-Mediated Neurological Disorders: Animal Models and Potential Implications. Frontiers in Neurology, 2019, 10, 1394.	2.4	20
63	Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight, 2019, 4, .	5.0	43
64	Immune or Genetic-Mediated Disruption of CASPR2 Causes Pain Hypersensitivity Due to Enhanced Primary Afferent Excitability. Neuron, 2018, 97, 806-822.e10.	8.1	119
65	Autoimmune neurological disorders-does the age matter?. European Journal of Paediatric Neurology, 2018, 22, 341-343.	1.6	3
66	Serological and experimental studies in different forms of myasthenia gravis. Annals of the New York Academy of Sciences, 2018, 1413, 143-153.	3.8	44
67	The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain, 2018, 141, 348-356.	7.6	272
68	Autoantibody Testing in theÂDiagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases. , 2018, , 153-168.		2
69	Acquired Neuromyotonia. , 2018, , 239-250.		0
70	Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain, 2018, 141, 13-36.	7.6	145
71	Brain-relevant antibodies in first-episode psychosis: a matched caseâ€“control study. Psychological Medicine, 2018, 48, 1257-1263.	4.5	22
72	Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody. Multiple Sclerosis Journal, 2018, 24, 679-684.	3.0	9

#	Article	IF	Citations
73	Antibody-mediated central nervous system diseases. Brain and Neuroscience Advances, 2018, 2, 239821281881749.	3.4	11
74	NMDA-receptor antibodies alter cortical microcircuit dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9916-E9925.	7.1	39
75	Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia. JAMA Neurology, 2018, 75, 1519.	9.0	43
76	Investigation of neuronal auto-antibodies in children diagnosed with epileptic encephalopathy of unknown cause. Brain and Development, 2018, 40, 909-917.	1.1	13
77	Glutamate receptor Î2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology, 2018, 91, e714-e723.	1.1	43
78	Plasma cell depletion with bortezomib in the treatment of refractory Nâ€methylâ€<scp>d</scp>â€aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment. European Journal of Neurology, 2018, 25, 1384-1388.	3.3	29
79	Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes. Seminars in Neurology, 2018, 38, 344-354.	1.4	28
80	Antiglycine receptor antibody related disease: a case series and literature review. European Journal of Neurology, 2018, 25, 1290-1298.	3.3	51
81	Do we need to measure specific antibodies in patients with limbic encephalitis?. Neurology, 2017, 88, 508-509.	1.1	9
82	Pediatric Autoimmune Epileptic Encephalopathies. Journal of Child Neurology, 2017, 32, 418-428.	1.4	13
83	Diagnostic algorithm for relapsing demyelinating syndromes of the CNS in children. Lancet, The, 2017, 389, S41.	13.7	2
84	Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 353-361.	1.9	124
85	First reported cases of anti-NMDA receptor encephalitis in Vietnamese adolescents and adults. Journal of the Neurological Sciences, 2017, 373, 250-253.	0.6	18
86	Recurrent Optic Neuritis Associated With MOG Antibody Seropositivity. Neurologist, 2017, 22, 101-102.	0.7	11
87	IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e357.	6.0	53
88	Redefining progressive encephalomyelitis with rigidity and myoclonus after the discovery of antibodies to glycine receptors. Current Opinion in Neurology, 2017, 30, 310-316.	3.6	34
89	Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy. Sleep, 2017, 40, .	1.1	32
90	CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 718-721.	1.9	41

#	Article	IF	Citations
91	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	1.9	108
92	Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain, 2017, 140, 617-627.	7.6	208
93	Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology, 2017, 89, 269-278.	1.1	155
94	Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain, 2017, 140, 1212-1219.	7.6	89
95	Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry,the, 2017, 4, 42-48.	7.4	143
96	Paraneoplastic cerebellar degeneration and lambertâ€eaton myasthenia in a patient with merkel cell carcinoma and voltageâ€gated calcium channel antibodies. Muscle and Nerve, 2017, 56, 998-1000.	2.2	11
97	IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. Journal of Autoimmunity, 2017, 77, 104-115.	6.5	92
98	High sensitivity and specificity in proposed clinical diagnostic criteria for antiâ€‹Nâ€methylâ€‹<scp>D</scp>â€aspartate receptor encephalitis. Developmental Medicine and Child Neurology, 2017, 59, 1256-1260.	2.1	46
99	Detection of NMDARs Antibodies in Encephalitis. Methods in Molecular Biology, 2017, 1677, 117-126.	0.9	5
100	Long-term outcomes of NMDAR-Ab encephalitis in U.K. cases. European Journal of Paediatric Neurology, 2017, 21, e7-e8.	1.6	0
101	Persistent microglial activation and synaptic loss with behavioral abnormalities in mouse offspring exposed to CASPR2-antibodies in utero. Acta Neuropathologica, 2017, 134, 567-583.	7.7	46
102	Pathogenic potential of antibodies to the <scp>GABA_B</scp> receptor. Epilepsia Open, 2017, 2, 355-359.	2.4	30
103	1633â€...Linear- versus conformational-protein directed autoantibodies in neuropsychiatric systemic lupus erythematosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A10.1-A10.	1.9	0
104	Cell- and Single Molecule-Based Methods to Detect Anti- N -Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project. Biological Psychiatry, 2017, 82, 766-772.	1.3	67
105	Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children. European Journal of Paediatric Neurology, 2017, 21, 414-417.	1.6	16
106	Voltage-Gated Potassium Channel Antibodies in Slow-Progression Motor Neuron Disease. Neurodegenerative Diseases, 2017, 17, 59-62.	1.4	3
107	Pitfalls in the detection of N -methyl- d -aspartate-receptor (NMDA-R) antibodies. Clinical Biochemistry, 2017, 50, 354-355.	1.9	18
108	Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain, 2017, 140, 3128-3138.	7.6	527

#	Article	IF	Citations
109	Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease. Acta Neuropathologica Communications, 2017, 5, 95.	5.2	35
110	Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Research, 2016, 5, 1513.	1.6	115
111	Progress in autoimmune epileptic encephalitis. Current Opinion in Neurology, 2016, 29, 151-157.	3.6	21
112	Characteristics Of acetylcholineâ€receptorâ€antibodyâ€“negative myasthenia gravis in a South African cohort. Muscle and Nerve, 2016, 54, 1023-1029.	2.2	31
113	Autoantibodies and pain. Current Opinion in Supportive and Palliative Care, 2016, 10, 137-142.	1.3	11
114	Anti-N-Methyl-D-Aspartate Receptor Encephalitis In A Young Child With Histological Evidence On Brain Biopsy Of Coexistent Herpes Simplex Virus Type 1 Infection. Pediatric Infectious Disease Journal, 2016, 35, 347-349.	2.0	15
115	Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies. Developmental Medicine and Child Neurology, 2016, 58, 836-841.	2.1	29
116	Nâ€methylâ€<scp>d</scp>â€aspartate (<scp>NMDA</scp>) receptor antibodies encephalitis mimicking an autistic regression. Developmental Medicine and Child Neurology, 2016, 58, 1092-1094.	2.1	34
117	I mmuno g lobuli N i n the T reatment of E ncephalitis (IgNiTE): protocol for a multicentre randomised controlled trial. BMJ Open, 2016, 6, e012356.	1.9	21
118	Stiff person syndrome in South Asia. BMC Research Notes, 2016, 9, 468.	1.4	3
119	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	1.9	228
120	The Importance of Keeping in Mind the Diagnosis of N -Methyl-D-Aspartate Receptor Encephalitis. Biological Psychiatry, 2016, 80, e15.	1.3	1
121	Autoimmunity in neuropsychiatric disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 269-282.	1.8	11
122	Autoimmune movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 301-315.	1.8	14
123	Introduction to autoimmune neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 3-14.	1.8	16
124	Voltage-gated potassium channelâ€“complex autoimmunity and associated clinical syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 185-197.	1.8	46
125	Neuromuscular junction disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 447-466.	1.8	51
126	Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 511-522.	27.0	695

#	Article	IF	Citations
127	Compromised fidelity of Bâ€cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Annals of Clinical and Translational Neurology, 2016, 3, 443-454.	3.7	39
128	Neuronal antibodies in pediatric epilepsy: Clinical features and longâ€term outcomes of a historical cohort not treated with immunotherapy. Epilepsia, 2016, 57, 823-831.	5.1	33
129	Postencephalitic epilepsy and drugâ€resistant epilepsy after infectious and antibodyâ€associated encephalitis in childhood: Clinical and etiologic risk factors. Epilepsia, 2016, 57, e7-e11.	5.1	54
130	Neuroimaging in encephalitis: analysis of imaging findings and interobserver agreement. Clinical Radiology, 2016, 71, 1050-1058.	1.1	49
131	Autoimmune synaptopathies. Nature Reviews Neuroscience, 2016, 17, 103-117.	10.2	81
132	Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome. Neurology, 2016, 86, 692-694.	1.1	10
133	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 676-677.	1.9	5
134	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	10.2	2,782
135	Antibodies to AMPA receptors in Rasmussen's encephalitis. European Journal of Paediatric Neurology, 2016, 20, 222-227.	1.6	15
136	Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. Neurotherapeutics, 2016, 13, 147-162.	4.4	78
137	Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings. Journal of Neurology, 2016, 263, 455-466.	3.6	42
138	Myasthenia gravis: a clinical-immunological update. Journal of Neurology, 2016, 263, 826-834.	3.6	124
139	Isolated new onset â€˜atypicalâ€™ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. Journal of Neurology, 2016, 263, 370-379.	3.6	51
140	Pregnancy outcomes in aquaporin-4â€“positive neuromyelitis optica spectrum disorder. Neurology, 2016, 86, 79-87.	1.1	95
141	N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness. Biological Psychiatry, 2016, 79, e61.	1.3	7
142	Autoantibody-associated autoimmune-encephalitis in Sri Lankan patients. Journal of the Neurological Sciences, 2015, 357, e195.	0.6	0
143	Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study. PLoS ONE, 2015, 10, e0143558.	2.5	28
144	Fetal acetylcholine receptor inactivation syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e57.	6.0	50

#	Article	IF	Citations
145	Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Experimental Neurology, 2015, 270, 66-71.	4.1	54
146	Antibodies to GABA _A receptor Î±1 and Î³2 subunits. Neurology, 2015, 84, 1233-1241.	1.1	159
147	Epileptogenic effects of NMDAR antibodies in a passive transfer mouse model. Brain, 2015, 138, 3159-3167.	7.6	88
148	Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e121.	6.0	14
149	Central nervous system antibody-mediated diseases with autonomic involvement â€“ Focus on VGKC-complex (LGI1, CASPR2), NMDAR and GlyR antibodies. Autonomic Neuroscience: Basic and Clinical, 2015, 192, 15.	2.8	1
150	Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 692-694.	1.9	48
151	Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions. Journal of Neurology, 2015, 262, 1081-1095.	3.6	30
152	Collagen Q â€“ A potential target for autoantibodies in myasthenia gravis. Journal of the Neurological Sciences, 2015, 348, 241-244.	0.6	45
153	Clinical relevance of serum antibodies to extracellularN-methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	1.9	97
154	Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 470-472.	1.9	90
155	Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis modelâ€"Recommendations for methods and experimental designs. Experimental Neurology, 2015, 270, 3-10.	4.1	25
156	OP87 â€“ 3001: Paediatric neurological syndromes associated with glycine receptor antibodies. European Journal of Paediatric Neurology, 2015, 19, S27.	1.6	0
157	PP14.3 â€“ 2698: Prolonged cortical hyperexcitability during burst-suppression associated with glycine receptor antibodies. European Journal of Paediatric Neurology, 2015, 19, S86-S87.	1.6	0
158	Paraneoplastic neurologic disorders in small cell lung carcinoma. Neurology, 2015, 85, 235-239.	1.1	99
159	Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. Experimental Neurology, 2015, 270, 29-40.	4.1	27
160	Targeting the Interleukin 6 Receptor to Treat Neuromyelitis Optica. JAMA Neurology, 2015, 72, 747.	9.0	4
161	Autoimmune Encephalopathies. Pediatric Clinics of North America, 2015, 62, 667-685.	1.8	27
162	An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre. Journal of Neurology, 2015, 262, 418-424.	3.6	37

#	Article	IF	Citations
163	Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurology, 2015, 72, 642.	9.0	118
164	Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e81.	6.0	205
165	Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome. Pediatrics, 2015, 135, e974-e984.	2.1	115
166	MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e89.	6.0	322
167	Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibodyâ€“Consuming Effect?. Journal of Neuropathology and Experimental Neurology, 2015, 74, 194-197.	1.7	6
168	N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children. Archives of Disease in Childhood, 2015, 100, 521-526.	1.9	112
169	Neuromyelitis optica in a child with Aicardi-GoutiÃˆres syndrome. Neurology, 2015, 85, 381-383.	1.1	22
170	Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e163.	6.0	203
171	GLYCINE RECEPTOR ANTIBODYâ€”A MARKER FOR NMO/ NON-MS DEMYELINATION?. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.36-e4.	1.9	0
172	A PROSPECTIVE CLINICAL AND IMMUNOLOGICAL STUDY OF LATE ONSET MYASTHENIA GRAVIS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.49-e4.	1.9	0
173	Neuroinflammation: Ways in Which the Immune System Affects the Brain. Neurotherapeutics, 2015, 12, 896-909.	4.4	170
174	Clinical relevance of voltage-gated potassium channelâ€“complex antibodies in children. Neurology, 2015, 85, 967-975.	1.1	57
175	Pediatric Herpes Simplex Virus Encephalitis Complicated by N-Methyl-D-aspartate Receptor Antibody Encephalitis. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e17-e21.	1.3	22
176	Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination. PLoS ONE, 2015, 10, e0129555.	2.5	17
177	Low Levels of Vitamin D in Neuromyelitis Optica Spectrum Disorder: Association with Disease Disability. PLoS ONE, 2014, 9, e107274.	2.5	31
178	Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 456-461.	1.9	70
179	NMDA receptor antibodies associated with distinct white matter syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e2.	6.0	85
180	Human African Trypanosomiasis Presenting at Least 29 Years after Infectionâ€”What Can This Teach Us about the Pathogenesis and Control of This Neglected Tropical Disease?. PLoS Neglected Tropical Diseases, 2014, 8, e3349.	3.0	60

#	Article	IF	Citations
181	Voltage-Gated Potassium Channels Autoantibodies in a Child with Rasmussen Encephalitis. Neuropediatrics, 2014, 45, 336-340.	0.6	6
182	RETROGRADE AMNESIA FOLLOWING AUTOIMMUNE LIMBIC ENCEPHALITIS. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.79-e4.	1.9	0
183	VGKC-complex antibody encephalitis. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 657-659.	0.5	4
184	Gerstmann-StraÃ¼ssler-Scheinker disease. Neurology, 2014, 82, 2107-2111.	1.1	24
185	Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop. Pain Medicine, 2014, 15, 1072-1082.	1.9	22
186	Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series. Schizophrenia Research, 2014, 160, 193-195.	2.0	62
187	EEG-confirmed epileptic activity in a cat with VGKC-complex/LGI1 antibody-associated limbic encephalitis. Epileptic Disorders, 2014, 16, 116-120.	1.3	23
188	Advances in the clinical science of the motor unit. Current Opinion in Neurology, 2014, 27, 503-505.	3.6	0
189	PREGNANCY OUTCOME IN AQUAPORIN-4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER: A MULTI-CENTER RETROSPECTIVE COHORT STUDY. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.74-e4.	1.9	0
190	IgG and Complement Deposition and Neuronal Loss in Cats and Humans With Epilepsy and Voltage-Gated Potassium Channel Complex Antibodies. Journal of Neuropathology and Experimental Neurology, 2014, 73, 403-413.	1.7	40
191	AUTOANTIBODIES IN ALZHEIMER DISEASE;. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e3-e3.	1.9	0
192	Features of Neuromyelitis Optica Spectrum Disorders and Aquaporin-4 With Myelin-Oligodendrocyte Glycoprotein Antibodiesâ€"Reply. JAMA Neurology, 2014, 71, 924.	9.0	15
193	How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Archives of Disease in Childhood, 2014, 99, 539-542.	1.9	79
194	The role of muscleâ€specific tyrosine kinase (<scp>MuSK</scp>) and mystery of <scp>MuSK</scp> myasthenia gravis. Journal of Anatomy, 2014, 224, 29-35.	1.5	39
195	Characterisation of a syndrome of autoimmune adult onset focal epilepsy and encephalitis. Journal of Clinical Neuroscience, 2014, 21, 1169-1175.	1.5	18
196	Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. Journal of Neuroimmunology, 2014, 271, 66-68.	2.3	30
197	Autoantibodies to the N-methyl-D-aspartate receptor and seizure susceptibility in mice. Lancet, The, 2014, 383, S111.	13.7	0
198	Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia, 2014, 55, 414-422.	5.1	66

#	Article	IF	Citations
199	Paraneoplastic cerebellar syndrome and sensory ganglionopathy with papillary thyroid carcinoma. Journal of the Neurological Sciences, 2014, 341, 183-184.	0.6	10
200	Myasthenia Gravis and Related Disorders. , 2014, , 777-791.		0
201	Hypoventilation in glycine-receptor antibody related progressive encephalomyelitis, rigidity and myoclonus. Journal of Clinical Neuroscience, 2014, 21, 876-878.	1.5	15
202	Nâ€methylâ€Dâ€aspartate receptor antibodyâ€associated movement disorder without encephalopathy. Developmental Medicine and Child Neurology, 2014, 56, 190-193.	2.1	30
203	Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurology, The, 2014, 13, 195-205.	10.2	352
204	Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies. JAMA Neurology, 2014, 71, 276.	9.0	519
205	Do Neuronal Autoantibodies Cause Psychosis? A Neuroimmunological Perspective. Biological Psychiatry, 2014, 75, 269-275.	1.3	55
206	Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha-1a adrenoceptors. Pain, 2014, 155, 2408-2417.	4.2	70
207	Cell-surface neuronal antibodies in patients with Japanese encephalitis virus. Journal of Neuroimmunology, 2014, 275, 6-7.	2.3	1
208	Glycine receptor antibody mediated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM): a rare but treatable neurological syndrome. Practical Neurology, 2014, 14, 123-127.	1.1	31
209	Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191.	2.3	54
210	Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain, 2014, 137, 2178-2192.	7.6	430
211	Nâ€methylâ€Dâ€aspartate receptor antibodies in postâ€herpes simplex virus encephalitis neurological relapse. Movement Disorders, 2014, 29, 90-96.	3.9	192
212	Autoantibodies at the neuromuscular junctionÂâ€Âlink to the central nervous system. Revue Neurologique, 2014, 170, 584-586.	1.5	1
213	Cellâ€surface central nervous system autoantibodies: Clinical relevance and emerging paradigms. Annals of Neurology, 2014, 76, 168-184.	5.3	159
214	Glycine receptor antibodies in a boy with focal epilepsy and episodic behavioral disorder. Journal of the Neurological Sciences, 2014, 343, 180-182.	0.6	30
215	Anti-NMDAR encephalitis misdiagnosed asÂHashimoto's encephalopathy. European Journal of Paediatric Neurology, 2014, 18, 72-74.	1.6	18
216	Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 625-630.	1.9	106

#	Article	IF	Citations
217	Limbic Encephalitis Associated With Elevated Antithyroid Antibodies. Journal of Child Neurology, 2014, 29, 769-773.	1.4	12
218	Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population. Journal of the Neurological Sciences, 2014, 343, 82-87.	0.6	28
219	Epilepsy-related psychosis: A role for autoimmunity?. Epilepsy and Behavior, 2014, 36, 33-38.	1.7	22
220	Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 2014, 261, 337-342.	4.1	14
221	Glycine receptor antibodies in 2 cases of new, adult-onset epilepsy. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e16.	6.0	14
222	Guillainâ€BarrÃ© syndrome associated with <scp>CASPR2</scp> antibodies: two paediatric cases. Journal of the Peripheral Nervous System, 2014, 19, 246-249.	3.1	17
223	Autoimmune Encephalitisâ€"Antibody Targets and Their Potential Pathogenicity in Immunotherapy-responsive Syndromes. European Neurological Review, 2014, 9, 87.	0.5	1
224	GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nature Genetics, 2013, 45, 1061-1066.	21.4	380
225	Long-term clinical course with voltage-gated potassium channel antibody in Morvanâ€™s syndrome. Journal of Neurology, 2013, 260, 2407-2408.	3.6	8
226	Autoantibodies in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurology, 2013, 70, 919.	9.0	34
227	Autoimmune myasthenia gravis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1465-1468.	1.8	19
228	CACNA1H antibodies associated with headache with neurological deficits and cerebrospinal fluid lymphocytosis (HaNDL). Cephalalgia, 2013, 33, 123-129.	3.9	37
229	Prevalence, clinical features and treatment outcomes of patients with myasthenia gravis positive for antibodies to muscle-specific kinase in Thailand. Journal of Clinical Neuroscience, 2013, 20, 707-709.	1.5	4
230	Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. Journal of the Neurological Sciences, 2013, 335, 221-223.	0.6	33
231	Developments in autoimmune channelopathies. Autoimmunity Reviews, 2013, 12, 678-681.	5.8	24
232	Organic neuropsychiatry: a treatable cause of suicidal behaviour. Practical Neurology, 2013, 13, 44-48.	1.1	1
233	Symptomatic brain involvement as the initial manifestation of neuromyelitis optica. Journal of Clinical Neuroscience, 2013, 20, 938-942.	1.5	9
234	Acute disseminated encephalomyelitis associated with positive voltage gated potassium channel complex antibody. Multiple Sclerosis and Related Disorders, 2013, 2, 147-150.	2.0	2

#	Article	IF	Citations
235	Neuromyelitis Optica IgG Causes Placental Inflammation and Fetal Death. Journal of Immunology, 2013, 191, 2999-3005.	0.8	90
236	N-Methyl-d-aspartate receptor (NMDAR) antibodies in post herpes simplex virus encephalitis (HSVE) neurological relapse. Journal of the Neurological Sciences, 2013, 333, e128.	0.6	1
237	Survivin Blockade Sensitizes Rhabdomyosarcoma Cells for Lysis by Fetal Acetylcholine Receptorâ€"Redirected T Cells. American Journal of Pathology, 2013, 182, 2121-2131.	3.8	15
238	HLA-DRB1 and HLA-DQB1 allele association to myasthenia gravis in Sudan; an Arabian-African population. Journal of the Neurological Sciences, 2013, 333, e478.	0.6	0
239	Suspected Limbic Encephalitis and Seizure in Cats Associated with Voltageâ€Gated Potassium Channel (<scp>VGKC</scp>) Complex Antibody. Journal of Veterinary Internal Medicine, 2013, 27, 212-214.	1.6	54
240	Ion channels in genetic and acquired forms of epilepsy. Journal of Physiology, 2013, 591, 753-764.	2.9	130
241	Progressive Encephalomyelitis with Rigidity and Myoclonus: A Syndrome with Diverse Clinical Features and Antibody Responses. European Neurology, 2013, 69, 257-262.	1.4	22
242	Autoimmune epilepsy in children: Case series and proposed guidelines for identification. Epilepsia, 2013, 54, 1036-1045.	5.1	76
243	A pilot study on neurological manifestations and antibodies against antigens in children with hematological and other cancers. European Journal of Paediatric Neurology, 2013, 17, 97-101.	1.6	4
244	Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain, 2013, 136, 3151-3162.	7.6	373
245	Progressive Encephalomyelitis With Rigidity and Myoclonus. JAMA Neurology, 2013, 70, 498.	9.0	51
246	Narcolepsy and H1N1 vaccination. Current Opinion in Pulmonary Medicine, 2013, 19, 587-593.	2.6	19
247	Neuronal Surface and Glutamic Acid Decarboxylase Autoantibodies in Nonparaneoplastic Stiff Person Syndrome. JAMA Neurology, 2013, 70, 1140.	9.0	56
248	Creutzfeld-Jakob Diseaseâ€"Reply. JAMA Neurology, 2013, 70, 1589.	9.0	1
249	Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 Antibodies. JAMA Neurology, 2013, 70, 1375.	9.0	100
250	Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 748-755.	1.9	217
251	Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia, 2013, 54, 1028-1035.	5.1	199
252	Immune-mediated pediatric epilepsies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 111, 521-531.	1.8	10

#	Article	IF	Citations
253	Guillain-BarrÃ©-like syndrome associated with lung adenocarcinoma and CASPR2 antibodies. Muscle and Nerve, 2013, 48, 836-837.	2.2	15
254	Autoantibodies to neuronal antigens in children with newâ€onset seizures classified according to the revised <scp>ILAE</scp> organization of seizures and epilepsies. Epilepsia, 2013, 54, 2091-2100.	5.1	54
255	MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. PLoS ONE, 2013, 8, e80695.	2.5	138
256	Acute Measles Encephalitis in Partially Vaccinated Adults. PLoS ONE, 2013, 8, e71671.	2.5	15
257	Immunization against GAD Induces Antibody Binding to GAD-Independent Antigens and Brainstem GABAergic Neuronal Loss. PLoS ONE, 2013, 8, e72921.	2.5	27
258	Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 437-440.	1.9	105
259	138â€…Differences in outcomes in neuromyelitis optica between a Japanese cohort and a predominantly Caucasian cohort from the UK. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.91-e1.	1.9	0
260	162â€…The association of two rare neurological diseases: a multicentre study of 16 patients with AChR antibody myasthenia gravis and AQP4 antibody neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.118-e1.	1.9	0
261	Antiâ€“Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia. Archives of Neurology, 2012, 69, 1064-6.	4.5	17
262	0842â€…Myelin-oligodendrocyte glycoprotein antibody as a cause of acute disseminated encephalomyelitis with a neuromyelitis optica-like phenotype in adults. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.152-e1.	1.9	0
263	Republished review: Autoantibody testing in encephalopathies. Postgraduate Medical Journal, 2012, 88, 280-289.	1.8	1
264	Febrile Infection-Related Epilepsy Syndrome without Detectable Autoantibodies and Response to Immunotherapy: A Case Series and Discussion of Epileptogenesis in FIRES. Neuropediatrics, 2012, 43, 209-216.	0.6	71
265	Antibody-mediated encephalitis: a treatable cause of schizophrenia. British Journal of Psychiatry, 2012, 200, 92-94.	2.8	94
266	Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis. Archives of Neurology, 2012, 69, 994-1001.	4.5	111
267	Paediatric autoimmune encephalitis: evaluation of clinical features, laboratory investigations and outcome. Archives of Disease in Childhood, 2012, 97, A135.1-A135.	1.9	0
268	094â€…Anti-NMDA receptor antibodies disrupt cortical network activity in vitro. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.42-e1.	1.9	0
269	The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arquivos De Neuro-Psiquiatria, 2012, 70, 300-304.	0.8	19
270	Laboratoriums Medizin, 2012, 35, ---.	0.6	3

#	Article	IF	Citations
271	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain, 2012, 135, 1834-1849.	7.6	361
272	More movements in neuroimmunology. Brain, 2012, 135, 3201-3202.	7.6	3
273	Supranuclear gaze palsy in glycine receptor antibodyâ€positive progressive encephalomyelitis with rigidity and myoclonus. Movement Disorders, 2012, 27, 1833-1834.	3.9	22
274	Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. Journal of Neurology, 2012, 259, 1566-1573.	3.6	51
275	NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. Journal of Neurology, 2012, 259, 1979-1981.	3.6	48
276	End of the bed (end of the video) diagnosis: Figure 1. Practical Neurology, 2012, 12, 135-138.	1.1	1
277	Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 638-645.	1.9	261
278	Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain, 2012, 135, 1622-1638.	7.6	549
279	Autoantibody testing in encephalopathies. Practical Neurology, 2012, 12, 4-13.	1.1	10
280	Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: A case report. Neuromuscular Disorders, 2012, 22, 546-548.	0.6	18
281	Serologic diagnosis of NMO. Neurology, 2012, 78, 665-671.	1.1	454
282	VGKCâ€complex antibody mediated encephalitis presenting with psychiatric features and neuroleptic malignant syndrome â€“ further expanding the phenotype. Developmental Medicine and Child Neurology, 2012, 54, 575-576.	2.1	14
283	A clinicoâ€radiological phenotype of voltageâ€gated potassium channel complex antibodyâ€mediated disorder presenting with seizures and basal ganglia changes. Developmental Medicine and Child Neurology, 2012, 54, 1157-1159.	2.1	8
284	Antibodies identified by cellâ€based assays in myasthenia gravis and associated diseases. Annals of the New York Academy of Sciences, 2012, 1274, 92-98.	3.8	39
285	The search for new antigenic targets in myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 123-128.	3.8	76
286	Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex. Journal of the Neurological Sciences, 2012, 312, 52-56.	0.6	23
287	Myasthenia gravis and neuromyelitis optica spectrum disorder. Neurology, 2012, 78, 1601-1607.	1.1	177
288	Neutrophil protease inhibition reduces neuromyelitis opticaâ€“immunoglobulin Gâ€“induced damage in mouse brain. Annals of Neurology, 2012, 71, 323-333.	5.3	153

#	Article	IF	Citations
289	Morvan syndrome: Clinical and serological observations in 29 cases. Annals of Neurology, 2012, 72, 241-255.	5.3	470
290	Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. Experimental Neurology, 2012, 234, 506-512.	4.1	112
291	Anti-N-Methyl-d-aspartate-receptor encephalitis: Cognitive profile in two children. European Journal of Paediatric Neurology, 2012, 16, 79-82.	1.6	19
292	Febrile infection-related epilepsy syndrome is not caused by SCN1A mutations. Epilepsy Research, 2012, 100, 194-198.	1.6	9
293	Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO. Acta Neurologica Scandinavica, 2012, 126, 287-291.	2.1	14
294	Management of suspected viral encephalitis in children â€“ Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group National Guidelines. Journal of Infection, 2012, 64, 449-477.	3.3	152
295	Limbic encephalitis in children and adolescents. Archives of Disease in Childhood, 2011, 96, 186-191.	1.9	140
296	Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS. Journal of Clinical Oncology, 2011, 29, 902-908.	1.6	210
297	Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. Journal of the Neurological Sciences, 2011, 301, 71-76.	0.6	36
298	Limbic encephalitis presenting as a post-partum psychiatric condition. Journal of the Neurological Sciences, 2011, 308, 152-154.	0.6	9
299	T242 A SERUM-BASED BIOASSAY FOR THE DIAGNOSIS OF COMPLEX REGIONAL PAIN SYNDROME. European Journal of Pain Supplements, 2011, 5, 48-48.	0.0	0
300	T243 AUTOIMMUNITY AGAINST THE BETA2 ADRENERGIC RECEPTOR AND MUSCARINIC 2 RECEPTOR IN COMPLEX REGIONAL PAIN SYNDROME. European Journal of Pain Supplements, 2011, 5, 48-48.	0.0	1
301	Paroxysmal EEG pattern in a child with N-methyl-d-aspartate receptor antibody encephalitis. Developmental Medicine and Child Neurology, 2011, 53, 764-767.	2.1	21
302	Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Developmental Medicine and Child Neurology, 2011, 53, 1053-1057.	2.1	113
303	Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies. Developmental Medicine and Child Neurology, 2011, 53, 1058-1060.	2.1	40
304	Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia, 2011, 52, 121-131.	5.1	99
305	Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia, 2011, 52, 12-17.	5.1	66
306	Potentially pathogenic autoantibodies associated with epilepsy and encephalitis in children and adults. Epilepsia, 2011, 52, 8-11.	5.1	35

#	Article	IF	Citations
307	T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. Journal of Neuroimmunology, 2011, 235, 27-32.	2.3	31
308	Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-BehÃ§et's disease. Journal of Neuroimmunology, 2011, 239, 91-97.	2.3	25
309	Autoimmunity against the Î²2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain, 2011, 152, 2690-2700.	4.2	160
310	Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurology, The, 2011, 10, 759-772.	10.2	549
311	Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. Journal of Neurology, 2011, 258, 464-470.	3.6	65
312	Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology, 2011, 258, 686-688.	3.6	277
313	Surviving stiff-person syndrome: a case report. Journal of Neurology, 2011, 258, 1898-1900.	3.6	4
314	A case of glycine-receptor antibody-associated encephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings. Journal of Neurology, 2011, 258, 2268-2270.	3.6	32
315	Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. Journal of Neurology, 2011, 258, 2176-2180.	3.6	25
316	NMDA Receptor Antibody Encephalitis. Current Neurology and Neuroscience Reports, 2011, 11, 298-304.	4.2	96
317	Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Annals of Neurology, 2011, 69, 892-900.	5.3	751
318	Antiglycine-receptor encephalomyelitis with rigidity. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1399-1401.	1.9	121
319	Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis/New serological markers for the differential diagnosis of autoimmune limbic encephalitis. Laboratoriums Medizin, 2011, 35, 329-342.	0.6	4
320	John Newsom-Davis: clinician-scientist and so much more. Brain, 2011, 134, 3755-3774.	7.6	5
321	VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology, 2011, 76, 1252-1255.	1.1	99
322	Progressive encephalomyelitis with rigidity and myoclonus: Resolution after thymectomy. Neurology, 2011, 76, 303-304.	1.1	53
323	Progressive encephalomyelitis with rigidity and myoclonus. Neurology, 2011, 77, 439-443.	1.1	92
324	Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis. Neurology India, 2011, 59, 47.	0.4	51

#	Article	IF	Citations
325	Autoimmune encephalitis – new awareness, challenging questions. Discovery Medicine, 2011, 11, 449-58.	0.5	40
326	Steroid-responsive recurrent limbic encephalitis associated with small cell lung cancer and neuropil antibodies. Acta Neurologica Belgica, 2011, 111, 139-42.	1.1	2
327	Autoimmune mediated neuromuscular junction defects. Current Opinion in Neurology, 2010, 23, 489-495.	3.6	72
328	Anti-N-methyl-D-aspartate receptor antibodies: A potentially treatable cause of encephalitis in the intensive care unit. Critical Care Medicine, 2010, 38, 679-682.	0.9	88
329	The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Current Opinion in Neurology, 2010, 23, 144-150.	3.6	103
330	N-methyl-D-aspartate limbic encephalitis: Diagnosis should respect well-recognized criteria. Critical Care Medicine, 2010, 38, 1615-1616.	0.9	1
331	Prospective Study into the Incidence of Lambert Eaton Myasthenic Syndrome in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 34-38.	1.1	54
332	Caspr2 Antibodies in Patients with Thymomas. Journal of Thoracic Oncology, 2010, 5, S277-S280.	1.1	68
333	Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. Journal of Neurology, 2010, 257, 920-925.	3.6	18
334	Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems. Journal of Clinical Immunology, 2010, 30, 97-102.	3.8	36
335	Anti-N-methyl-D-Aspartate-Receptor Encephalitis in a Four-Year-Old Girl. Journal of Pediatrics, 2010, 156, 332-334.	1.8	20
336	Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Annals of Neurology, 2010, 67, 470-478.	5.3	429
337	Cerebrospinal fluid hypocretin levels are normal in idiopathic REM sleep behaviour disorder. European Journal of Neurology, 2010, 17, 1105-1107.	3.3	15
338	Bickerstaffâ€™s encephalitis and Miller Fisher syndrome associated with voltageâ€gated potassium channel and novel antiâ€neuronal antibodies. European Journal of Neurology, 2010, 17, 1304-1307.	3.3	17
339	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia, 2010, 51, 1898-1901.	5.1	43
340	PAW33 Aquaporin-4 M 23 isoform provides a more sensitive assay for aquaporin-4 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e32-e32.	1.9	4
341	Successful treatment of antiN-methyl-d-aspartate receptor limbic encephalitis in a 22-monthold child with plasmapheresis and pharmacological immunomodulation. Archives of Disease in Childhood, 2010, 95, 312-312.	1.9	38
342	The Association of Bullous Pemphigoid With Cerebrovascular Disease and Dementia. Archives of Dermatology, 2010, 146, 1251-4.	1.4	111

#	Article	IF	Citations
343	Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain, 2010, 133, 349-361.	7.6	480
344	Successful 'passive transfer' of paraneoplastic stiff person syndrome with antibodies to an intracellular antigen. Brain, 2010, 133, 3164-3165.	7.6	12
345	PATU1 Characteristic faciobrachial dystonic seizures as an immunotherapy-responsive prodrome to voltage-gated potassium channel antibody-associated limbic encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e24-e24.	1.9	0
346	Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain, 2010, 133, 2727-2733.	7.6	29
347	Interferon Beta Treatment in Neuromyelitis Optica. Archives of Neurology, 2010, 67, 1016-7.	4.5	295
348	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences, 2010, 298, 158-162.	0.6	169
349	N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain, 2010, 133, 1655-1667.	7.6	900
350	Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvanâ€™s syndrome and acquired neuromyotonia. Brain, 2010, 133, 2734-2748.	7.6	1,158
351	Anti-NMDA Receptor Encephalitis With Atypical Brain Changes on MRI. Pediatric Neurology, 2010, 43, 274-278.	2.1	17
352	Non-paraneoplastic limbic encephalitis characterized by mesio-temporal seizures and extratemporal lesions: A case report. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 446-449.	2.0	17
353	Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infectious Diseases, The, 2010, 10, 835-844.	9.1	1,107
354	SjÃ¶grenâ€™s syndrome myelopathy: spinal cord involvement in SjÃ¶grenâ€™s syndrome might be a manifestation of neuromyelitis optica. Multiple Sclerosis Journal, 2009, 15, 1062-1068.	3.0	70
355	Immunocapture and Identification of Cell Membrane Protein Antigenic Targets of Serum Autoantibodies. Molecular and Cellular Proteomics, 2009, 8, 1688-1696.	3.8	8
356	ENDPLATE DESTRUCTION DUE TO MATERNAL ANTIBODIES IN ARTHROGRYPOSIS MULTIPLEX CONGENITA. Neurology, 2009, 73, 1806-1808.	1.1	17
357	Successful treatment of anti-N-methyl-D-aspartate receptor encephalitis presenting with catatonia. Archives of Disease in Childhood, 2009, 94, 314-316.	1.9	69
358	Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women With New-Onset Epilepsy. Archives of Neurology, 2009, 66, 458-64.	4.5	158
359	Corrigendum to â€œAutoimmune channelopathies: John Newsom-Davis's work and legacy: A summary of the Newsom-Davis Memorial Lecture 2008â€•[J. Neuroimmunol. 201â€“202 (2008) 245â€“249]. Journal of Neuroimmunology, 2009, 210, 131.	2.3	1
360	P265 Anti-NMDAR auto-immune encephalitis. European Journal of Paediatric Neurology, 2009, 13, S103-S104.	1.6	0

#	Article	IF	Citations
361	Nâ€methylâ€<scp>D</scp>â€aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Annals of Neurology, 2009, 66, 704-709.	5.3	223
362	371 EFFECT OF THE INJECTION OF CRPS IgG SERUM FRACTION IN MICE. European Journal of Pain, 2009, 13, S112a.	2.8	0
363	Autoimmune disorders of the neuromuscular junction. Current Opinion in Pharmacology, 2009, 9, 336-340.	3.5	50
364	Immune-mediated rippling muscle disease with myasthenia gravis: A report of seven patients with long-term follow-up in two. Neuromuscular Disorders, 2009, 19, 223-228.	0.6	36
365	MuSK-antibody-positive myasthenia gravis in a South Asian population. Journal of the Neurological Sciences, 2009, 284, 33-35.	0.6	16
366	Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Multiple Sclerosis Journal, 2009, 15, 1069-1076.	3.0	59
367	The Effect of Plasma From Muscle-Specific Tyrosine Kinase Myasthenia Patients on Regenerating Endplates. American Journal of Pathology, 2009, 175, 1536-1544.	3.8	37
368	Anti-NMDA receptor encephalitis: aÂvideo case report. Epileptic Disorders, 2009, 11, 267-269.	1.3	11
369	Autoimmune channelopathies: new antibody-mediated disorders of the central nervous system. F1000 Biology Reports, 2009, 1, 61.	4.0	10
370	Relative frequency of VGKC and â€˜classicalâ€™ paraneoplastic antibodies in patients with limbic encephalitis. Journal of Neurology, 2008, 255, 1100-1101.	3.6	25
371	New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin. Journal of Neurology, 2008, 255, 1603-1604.	3.6	9
372	Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies. Annals of the New York Academy of Sciences, 2008, 1132, 84-92.	3.8	93
373	Autoimmunizing Mechanisms in Thymoma and Thymus*. Annals of the New York Academy of Sciences, 2008, 1132, 163-173.	3.8	68
374	Congenital Myasthenic Syndromes and the Formation of the Neuromuscular Junction. Annals of the New York Academy of Sciences, 2008, 1132, 99-103.	3.8	29
375	MuSKâ€positive myasthenia gravis is rare in the Polish population. European Journal of Neurology, 2008, 15, 720-724.	3.3	28
376	Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. Journal of Neuroimmunology, 2008, 195, 151-156.	2.3	122
377	Autoimmune channelopathies: John Newsom-Davis's work and legacy. Journal of Neuroimmunology, 2008, 201-202, 245-249.	2.3	11
378	CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. Journal of the Neurological Sciences, 2008, 268, 74-77.	0.6	76

#	Article	IF	Citations
379	Autoantibodies in different forms of myasthenia gravis and in the Lambertâ€“Eaton syndrome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 91, 213-227.	1.8	2
380	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. Nature Clinical Practice Neurology, 2008, 4, 202-214.	2.5	286
381	Stiff, twitchy or wobblyâ€”are GAD antibodies pathogenic?. Brain, 2008, 131, 2536-2537.	7.6	35
382	Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis. Archives of Neurology, 2008, 65, 913-9.	4.5	259
383	IMMUNOTHERAPY-REVERSED COMPULSIVE, MONOAMINERGIC, CIRCADIAN RHYTHM DISORDER IN MORVAN SYNDROME. Neurology, 2008, 71, 2008-2010.	1.1	24
384	FETAL ACETYLCHOLINE RECEPTOR INACTIVATION SYNDROME AND MATERNAL MYASTHENIA GRAVIS. Neurology, 2008, 71, 2010-2012.	1.1	48
385	PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY. Neurology, 2008, 71, 1291-1292.	1.1	324
386	IgG1 antibodies to acetylcholine receptors in â€˜seronegativeâ€™ myasthenia gravisâ€. Brain, 2008, 131, 1940-1952.	7.6	438
387	Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain, 2008, 131, 3072-3080.	7.6	397
388	Autoimmune disorders of the neuromuscular junction. Neurology India, 2008, 56, 305.	0.4	23
389	Autoantibodies in neuromuscular transmission disorders. Annals of Indian Academy of Neurology, 2008, 11, 140.	0.5	3
390	Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. International MS Journal, 2008, 15, 99-105.	0.3	84
391	Paraneoplastic chronic demyelinating neuropathy and Lambert-Eaton myasthenic syndrome associated with multiple anti-neural antibodies and small-cell lung cancer. Ideggyogyaszati Szemle, 2008, 61, 325-8.	0.7	1
392	John Newsom-Davis, 1932â€“2007. Nature Clinical Practice Neurology, 2007, 3, 647-647.	2.5	0
393	Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scandinavian Journal of Gastroenterology, 2007, 42, 1289-1293.	1.5	48
394	Limbic Encephalitis: Under-Recognition of Voltage-Gated Potassium Channel Antibodies. European Neurology, 2007, 58, 184-184.	1.4	3
395	Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies. Clinical Neurophysiology, 2007, 118, 269-277.	1.5	38
396	Overexpression of Rapsyn in Rat Muscle Increases Acetylcholine Receptor Levels in Chronic Experimental Autoimmune Myasthenia Gravis. American Journal of Pathology, 2007, 170, 644-657.	3.8	33

#	Article	IF	Citations
397	Myasthenia Gravis Thymus. American Journal of Pathology, 2007, 171, 893-905.	3.8	113
398	Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nature Medicine, 2007, 13, 1483-1489.	30.7	373
399	An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature, 2007, 448, 934-937.	27.8	167
400	Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. Journal of Neuroimmunology, 2007, 185, 136-144.	2.3	36
401	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. PLoS Medicine, 2007, 4, e133.	8.4	187
402	MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain, 2006, 129, 1481-1492.	7.6	160
403	MuSK antibody-positive, seronegative myasthenia gravis in Korea. Journal of Clinical Neuroscience, 2006, 13, 353-355.	1.5	35
404	Autoimmune Channelopathies and Related Neurological Disorders. Neuron, 2006, 52, 123-138.	8.1	104
405	Fetal arthrogryposis and maternal serum antibodies. Neuromuscular Disorders, 2006, 16, 481-491.	0.6	31
406	Immunology of disorders of neuromuscular transmission. Acta Neurologica Scandinavica, 2006, 113, 1-7.	2.1	201
407	Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Research, 2006, 71, 135-141.	1.6	133
408	A 45-year history of acquired autoimmune neuromyotonia. Journal of Neurology, 2006, 253, 1243-1245.	3.6	1
409	Paraneoplastic neurological syndromes. State of the art. Journal of Neuroimmunology, 2006, 174, 192-204.	2.3	0
410	Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: The role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Movement Disorders, 2006, 21, 1737-1741.	3.9	61
411	Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle and Nerve, 2006, 33, 568-570.	2.2	55
412	Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Annals of Neurology, 2006, 59, 178-181.	5.3	213
413	Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain, 2006, 129, 1570-1584.	7.6	144
414	Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations. Brain, 2006, 129, 2773-2783.	7.6	50

#	Article	IF	Citations
415	Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology, 2006, 66, 1772-1774.	1.1	114
416	Acquired Neuromyotonia Precipitated by Thyroid Surgery and Associated with Antiacetylcholine Receptor Antibodies. European Neurology, 2006, 55, 222-224.	1.4	0
417	Dok-7 Mutations Underlie a Neuromuscular Junction Synaptopathy. Science, 2006, 313, 1975-1978.	12.6	247
418	Rhabdomyosarcoma Lysis by T Cells Expressing a Human Autoantibody-Based Chimeric Receptor Targeting the Fetal Acetylcholine Receptor. Cancer Research, 2006, 66, 24-28.	0.9	45
419	Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Current Opinion in Neurology, 2005, 18, 519-525.	3.6	127
420	Myasthenia gravis with MuSK antibodies. Practical Neurology, 2005, 5, 356-359.	1.1	6
421	Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. British Journal of Pharmacology, 2005, 146, 1027-1039.	5.4	123
422	FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology. Acta Neurologica Scandinavica, 2005, 111, 338-343.	2.1	52
423	Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation. Journal of Neuroimmunology, 2005, 162, 149-156.	2.3	23
424	Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome. Journal of Neuroimmunology, 2005, 162, 184-189.	2.3	43
425	Anti-glial nuclear antibody: Marker of lung cancer-related paraneoplastic neurological syndromes. Journal of Neuroimmunology, 2005, 165, 166-171.	2.3	117
426	MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. Journal of Neuroimmunology, 2005, 170, 41-48.	2.3	55
427	Acetylcholine receptors loss and postsynaptic damage in MuSK antibodyâ€“positive myasthenia gravis. Annals of Neurology, 2005, 57, 289-293.	5.3	164
428	Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Annals of Neurology, 2005, 57, 444-448.	5.3	216
429	Antibodies associated with paraneoplastic neurological disorders. Neurological Sciences, 2005, 26, s3-s4.	1.9	5
430	Thymoma-Associated Neuromyotonia with Antibodies against Voltage-Gated Potassium Channels Presenting as Chronic Intestinal Pseudo-Obstruction. European Neurology, 2005, 53, 60-63.	1.4	38
431	Fasciculations, Autonomic Symptoms and Limbic Encephalitis: A Thymoma-Associated Morvanâ€™s-Like Syndrome. European Neurology, 2005, 54, 235-237.	1.4	13
432	Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 714-718.	1.9	60

#	Article	IF	Citations
433	Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain, 2005, 128, 2327-2337.	7.6	66
434	Autoimmune channelopathies. Nature Clinical Practice Neurology, 2005, 1, 22-33.	2.5	64
435	Mechanisms in myasthenia gravis. Drug Discovery Today Disease Mechanisms, 2005, 2, 401-408.	0.8	2
436	Temporal lobe seizures, amnesia and autoantibodies - identifying a potentially reversible form of non-paraneoplastic limbic encephalitis. Epileptic Disorders, 2005, 7, 177-9.	1.3	4
437	Pilomotor seizures and status in non-paraneoplastic limbic encephalitis. Epileptic Disorders, 2005, 7, 205-11.	1.3	26
438	Seronegative Myasthenia Gravis. Seminars in Neurology, 2004, 24, 125-133.	1.4	82
439	A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition. Human Molecular Genetics, 2004, 13, 2947-2957.	2.9	29
440	Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology, 2004, 63, 43-50.	1.1	119
441	Encephalitis lethargica: part of a spectrum of post-streptococcal autoimmune diseases?. Brain, 2004, 127, 2-3.	7.6	38
442	Low-voltage-activated A-current controls the firing dynamics of mouse hypothalamic orexin neurons. European Journal of Neuroscience, 2004, 20, 3281-3285.	2.6	31
443	Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Annals of Neurology, 2004, 55, 580-584.	5.3	391
444	Lack of association between acetylcholine receptor ? polymorphisms and early-onset myasthenia gravis. Muscle and Nerve, 2004, 29, 436-439.	2.2	9
445	Potassium channel antibodyâ€associated encephalopathy: a potentially immunotherapyâ€responsive form of limbic encephalitis. Brain, 2004, 127, 701-712.	7.6	1,072
446	Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders, 2004, 14, 356-364.	0.6	59
447	Myasthenia Gravis. Autoimmunity, 2004, 37, 317-319.	2.6	21
448	Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain, 2004, 127, 269-279.	7.6	52
449	Chapter 16 Antibody-mediated disorders of neuromuscular transmission. Supplements To Clinical Neurophysiology, 2004, 57, 147-158.	2.1	6
450	Structural Abnormalities of the AChR Caused by Mutations Underlying Congenital Myasthenic Syndromes. Annals of the New York Academy of Sciences, 2003, 998, 114-124.	3.8	6

#	Article	IF	Citations
451	Pathogenic Autoantibodies in the Lambert-Eaton Myasthenic Syndrome. Annals of the New York Academy of Sciences, 2003, 998, 187-195.	3.8	40
452	LEMS IgG Binds to Extracellular Determinants on N-Type Voltage-Gated Calcium Channels, but Does Not Reduce VGCC Expression. Annals of the New York Academy of Sciences, 2003, 998, 196-199.	3.8	6
453	Autoimmune Disorders of Neuronal Potassium Channels. Annals of the New York Academy of Sciences, 2003, 998, 202-210.	3.8	114
454	Scenarios for Autoimmunization of T and B Cells in Myasthenia Gravis. Annals of the New York Academy of Sciences, 2003, 998, 237-256.	3.8	63
455	Antibodies in Myasthenia Gravis and Related Disorders. Annals of the New York Academy of Sciences, 2003, 998, 324-335.	3.8	103
456	Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurology, The, 2003, 2, 99-106.	10.2	216
457	Maternal neuronal antibodies associated with autism and a language disorder. Annals of Neurology, 2003, 53, 533-537.	5.3	193
458	Hu and VGCC Antibodies Related to the Prognosis of Small Cell Lung Cancer. Acta Neurologica Scandinavica, 2003, 107, 431-431.	2.1	0
459	Antibodies to Neuronal Targets in Neurological and Psychiatric Diseases. Annals of the New York Academy of Sciences, 2003, 992, 48-55.	3.8	26
460	Amnesia, cerebral atrophy, and autoimmunity. Lancet, The, 2003, 361, 1266.	13.7	40
461	Autoantibodies to ion channels at the neuromuscular junction. Autoimmunity Reviews, 2003, 2, 94-100.	5.8	58
462	Clinical aspects of MuSK antibody positive seronegative MG. Neurology, 2003, 60, 1978-1980.	1.1	389
463	Evidence of underdiagnosis of myasthenia gravis in older people. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1105-1108.	1.9	180
464	Spontaneous production of anti-IFN-Â and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. International Immunology, 2003, 15, 903-913.	4.0	65
465	Antibodies against Muscle-Specific Kinase in Juvenile Myasthenia Gravis. Neuropediatrics, 2003, 34, 110-111.	0.6	4
466	New autoantibody mediated disorders of the central nervous system. Current Opinion in Neurology, 2003, 16, 351-357.	3.6	43
467	Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients. European Cytokine Network, 2003, 14, 154-7.	2.0	9
468	AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology, 2002, 59, 1682-1688.	1.1	73

#	Article	IF	Citations
469	Mutations in congenital myasthenic syndromes reveal an varepsilon subunit C-terminal cysteine, C470, crucial for maturation and surface expression of adult AChR. Human Molecular Genetics, 2002, 11, 3087-3096.	2.9	37
470	Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain, 2002, 125, 1887-1895.	7.6	419
471	A Role for Autoantibodies in Some Cases of Acquired Non-Paraneoplastic Gut Dysmotility. Scandinavian Journal of Gastroenterology, 2002, 37, 166-170.	1.5	39
472	Diseases of the neuromuscular junction. Current Opinion in Pharmacology, 2002, 2, 296-301.	3.5	32
473	Expression of foetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disorders. Brain, 2002, 125, 1309-1319.	7.6	47
474	Reflections on the VIth International Congress of Neuroimmunology held at the Edinburgh International Conference Centre, Edinburgh, September 3â€“7, 2001. Journal of Neuroimmunology, 2002, 124, 1-3.	2.3	2
475	Maternal antibody-mediated dyslexia? Evidence for a pathogenic serum factor in a mother of two dyslexic children shown by transfer to mice using behavioural studies and magnetic resonance spectroscopy. Journal of Neuroimmunology, 2002, 130, 243-247.	2.3	27
476	Measuring and evaluating the significance of autoantibodies in neurological disorders. Clinical and Applied Immunology Reviews, 2002, 3, 127-151.	0.4	9
477	Antibodies to Acetylcholine Receptor in Parous Women with Myasthenia: Evidence for Immunization by Fetal Antigen. Laboratory Investigation, 2002, 82, 1407-1417.	3.7	45
478	Unravelling the pathogenesis of myasthenia gravis. Nature Reviews Immunology, 2002, 2, 797-804.	22.7	366
479	Determination of anti-acetylcholine receptor antibodies in myasthenic patients by use of time-resolved fluorescence. Clinical Chemistry, 2002, 48, 549-54.	3.2	2
480	Myasthenia gravis. Advances in Neurology, 2002, 88, 159-88.	0.8	27
481	Myasthenia gravis: diagnostic and management dilemmas. Current Opinion in Neurology, 2001, 14, 583-589.	3.6	36
482	Stiff-Person Syndrome: Autoimmunity and the Central Nervous System. CNS Spectrums, 2001, 6, 427-433.	1.2	18
483	Potassium channel antibodies in two patients with reversible limbic encephalitis. Annals of Neurology, 2001, 50, 73-78.	5.3	381
484	Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine, 2001, 7, 365-368.	30.7	1,083
485	Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. Journal of Neuroimmunology, 2001, 113, 153-162.	2.3	53
486	Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration. Journal of Neuroimmunology, 2001, 114, 259-264.	2.3	26

#	Article	IF	Citations
487	Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. Journal of Neuroimmunology, 2001, 115, 127-134.	2.3	38
488	Cerebellar Ataxia With Antiâ€“Glutamic Acid Decarboxylase Antibodies. Archives of Neurology, 2001, 58, 225.	4.5	371
489	End-plate gamma- and varepsilon-subunit mRNA levels in AChR deficiency syndrome due to varepsilon-subunit null mutations. Brain, 2001, 124, 1362-1372.	7.6	50
490	Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain, 2001, 124, 2417-2426.	7.6	347
491	Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology, 2001, 57, 1579-1582.	1.1	101
492	Acetylcholine receptor Î´ subunit mutations underlie a fast-channel myasthenic syndrome and arthrogryposis multiplex congenita. Journal of Clinical Investigation, 2001, 108, 125-130.	8.2	38
493	Asymptomatic maternal myasthenia as a cause of the Pena-Shokeir phenotype. , 2000, 92, 1-6.		61
494	Teratogen update: Maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology, 2000, 62, 332-341.	1.6	119
495	The spectrum of mutations causing end-plate acetylcholinesterase deficiency. Annals of Neurology, 2000, 47, 162-170.	5.3	123
496	Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. FEBS Journal, 2000, 267, 6717-6728.	0.2	71
497	Neuroprotective autoimmunityâ€”a double-edged sword?. Nature Medicine, 2000, 6, 383-385.	30.7	1
498	Persistent facial myokymia: an autoimmune aetiology?. Journal of Neurology, 2000, 247, 554-555.	3.6	9
499	Morvanâ€™s syndrome associated with voltage-gated K channel antibodies. Neurology, 2000, 54, 771-771.	1.1	126
500	Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia. Archives of Neurology, 2000, 57, 527.	4.5	87
501	Autoantibody screening in subacute cerebellar ataxia. Lancet, The, 2000, 356, 565-566.	13.7	35
502	Neuromyotonia in association with essential thrombocythemia. Journal of the Neurological Sciences, 2000, 173, 78-79.	0.6	8
503	Teratogen update: Maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology, 2000, 62, 332-341.	1.6	4
504	Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. FEBS Journal, 2000, 267, 6717-6728.	0.2	2

#	Article	IF	Citations
505	IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Annals of Neurology, 2000, 47, 504-10.	5.3	7
506	Neuromyotonia in association with systemic sclerosis. Journal of Neurology, 1999, 246, 976-977.	3.6	11
507	Monoclonal antibodies raised against human acetylcholine receptor bind to all five subunits of the fetal isoform. Journal of Neuroimmunology, 1999, 98, 112-120.	2.3	29
508	Pathogenic autoantibodies to neuronal proteins in neurological disorders. Journal of Neuroimmunology, 1999, 100, 169-180.	2.3	50
509	Physicochemical and immunological studies of the N-terminal domain Ã¯Â¿Â½of theTorpedoacetylcholine receptor Î±-subunit expressed in Ã¯Â¿Â½Escherichia coli. FEBS Journal, 1999, 259, 310-319.	0.2	33
510	Immune-mediated peripheral neuropathies and voltage-gated sodiums channels. , 1999, 22, 108-110.		19
511	A Comparison of MyoD1 and Fetal Acetylcholine Receptor Expression in Childhood Tumors and Normal Tissues. Journal of Molecular Diagnostics, 1999, 1, 23-31.	2.8	29
512	[36] Antibodies to ion channels. Methods in Enzymology, 1999, 294, 677-704.	1.0	0
513	Antibodies to Ion Channels in Paraneoplastic Disorders. Brain Pathology, 1999, 9, 285-291.	4.1	24
514	Immunology of the neuromuscular junction and presynaptic nerve terminal. Current Opinion in Neurology, 1999, 12, 545-551.	3.6	11
515	Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. Journal of Clinical Investigation, 1999, 103, 1031-1038.	8.2	72
516	Genetic and antibody-mediated channelopathies at the neuromuscular junction. Electroencephalography and Clinical Neurophysiology Supplement, 1999, 50, 250-8.	0.0	1
517	Neuronal Staining Patterns in Sera from Patients with Lambert-Eaton Myasthenic Syndromea. Annals of the New York Academy of Sciences, 1998, 841, 684-686.	3.8	1
518	Evidence for an Association between Human Acetylcholine Receptor and Rapsyna. Annals of the New York Academy of Sciences, 1998, 841, 14-16.	3.8	4
519	Congenital Myasthenic Syndromes: Studies of the AChR and Other Candidate Genesa. Annals of the New York Academy of Sciences, 1998, 841, 181-183.	3.8	9
520	A Single Nucleotide Deletion in the e Subunit of the Acetylcholine Receptor (AChR) in Five Congenital Myasthenic Syndrome Patients with AChR Deficiencya. Annals of the New York Academy of Sciences, 1998, 841, 195-198.	3.8	11
521	Thymus, Thymoma, and Specific T Cells in Myasthenia Gravisa. Annals of the New York Academy of Sciences, 1998, 841, 371-387.	3.8	21
522	Muscle Nicotinic Acetylcholine Receptor mRNA Expression in Hyperplastic and Neoplastic Myasthenia Gravis Thymusa. Annals of the New York Academy of Sciences, 1998, 841, 407-410.	3.8	15

#	Article	IF	Citations
523	Expression of Muscle Proteins in Thymomas of Patients with Myasthenia Gravisa. Annals of the New York Academy of Sciences, 1998, 841, 411-413.	3.8	5
524	Production of Fab Fragments against the Human Acetylcholine Receptor from Myasthenia Gravis Thymus Lambda and Kappa Phage Librariesa. Annals of the New York Academy of Sciences, 1998, 841, 418-421.	3.8	5
525	Antibodies Affecting Ion Channel Function in Acquired Neuromyotonia, in Seropositive and Seronegative Myasthenia Gravis, and in Antibody-mediated Arthrogryposis Multiplex Congenita. Annals of the New York Academy of Sciences, 1998, 841, 482-496.	3.8	39
526	Seronegative Myasthenia Plasmas and Non-IgG Fractions Transiently Inhibit nAChR Functiona. Annals of the New York Academy of Sciences, 1998, 841, 501-504.	3.8	9
527	An Animal Model of Maternal Antibodymediated Arthrogryposis Multiplex Congenita (AMC)a. Annals of the New York Academy of Sciences, 1998, 841, 565-567.	3.8	9
528	The Role of Autoantibodies in Lambert-Eaton Myasthenic Syndromeaa. Annals of the New York Academy of Sciences, 1998, 841, 596-605.	3.8	36
529	Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunological Reviews, 1998, 164, 157-168.	6.0	94
530	Antibodies to voltage-gated (VG) ion channels and glutamic acid decarboxylase (CAD) in childhood forms of epilepsies. Journal of Neuroimmunology, 1998, 90, 92.	2.3	0
531	IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody- mediated disease. European Journal of Immunology, 1998, 28, 2487-2497.	2.9	101
532	Epitopes expressed in myasthenia gravis (MG) thymomas are not recognized by patients' T cells or autoantibodies. Clinical and Experimental Immunology, 1998, 112, 17-20.	2.6	21
533	Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFNÎ³ secretion and cytotoxicity. Journal of Neuroimmunology, 1998, 86, 53-62.	2.3	32
534	Î± -Bungarotoxin binding to human muscle acetylcholine receptor: measurement of affinity, delineation of AChR subunit residues crucial to binding, and protection of AChR function by synthetic peptides. Neurochemistry International, 1998, 32, 427-433.	3.8	15
535	A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.. Journal of Clinical Investigation, 1998, 101, 2268-2277.	8.2	70
536	The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. American Journal of Pathology, 1998, 152, 437-44.	3.8	29
537	Antibodies to 125I-glutamic acid decarboxylase in patients with stiff man syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 395-397.	1.9	28
538	Postsynaptic Abnormalities at the Neuromuscular Junctions of Utrophin-deficient Mice. Journal of Cell Biology, 1997, 136, 883-894.	5.2	212
539	Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library. International Immunology, 1997, 9, 1311-1318.	4.0	48
540	Mutations in Different Functional Domains of the Human Muscle Acetylcholine Receptor Â Subunit in Patients with the Slow-Channel congenital Myasthenic Syndrome. Human Molecular Genetics, 1997, 6, 767-774.	2.9	147

#	Article	IF	Citations
541	Mechanisms of Action of Antiâ€GM₁and Antiâ€GQ_{1b}Ganglioside Antibodies in Guillainâ€BarrÃ© Syndrome. Journal of Infectious Diseases, 1997, 176, S144-S149.	4.0	37
542	Congenital myasthenic syndromes. Current Opinion in Neurology, 1997, 10, 402-407.	3.6	15
543	Heterogeneity and immunotherapy of specific T-cells in myasthenia gravis. Biochemical Society Transactions, 1997, 25, 665-670.	3.4	4
544	Disorders of the Human Neuromuscular Junction. Advances in Organ Biology, 1997, 2, 315-349.	0.1	4
545	Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Journal of the Neurological Sciences, 1997, 147, 35-42.	0.6	236
546	Identification of phospholipase A2 and neurotoxic activities in the venom of the New Guinean small-eyed snake (Micropechis ikaheka). Toxicon, 1997, 35, 101-109.	1.6	10
547	Spontaneous neutralising antibodies to interferon-a and interleukin-12 in thymoma-associated autoimmune disease. Lancet, The, 1997, 350, 1596-1597.	13.7	97
548	Lack of effect of Miller Fisher sera/plasmas on transmitter release from PC12 cells. Journal of Neuroimmunology, 1997, 80, 1-5.	2.3	10
549	Genes at the junctionâ€"candidates for congenital myasthenic syndromes. Trends in Neurosciences, 1997, 20, 15-22.	8.6	60
550	Antibodies specific for fetal AChR induce arthrogryposis multiplex congenita in developing mice: an animal model for transfer of pathogenic antibodies. Journal of Reproductive Immunology, 1997, 34, 95-96.	1.9	0
551	Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Annals of Neurology, 1997, 41, 238-246.	5.3	328
552	Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Annals of Neurology, 1997, 41, 423-431.	5.3	92
553	Stable functional expression of the adult subtype of human muscle acetylcholine receptor following transfection of the human rhabdomyosarcoma cell line TE671 with cDNA encoding the Îµ subunit. Neuroscience Letters, 1996, 207, 57-60.	2.1	50
554	Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis. Journal of Neuroimmunology, 1996, 64, 179-183.	2.3	31
555	Cloning of cDNA Encoding Human Rapsyn and Mapping of the RAPSN Gene Locus to Chromosome 11p11.2â€"p11.1. Genomics, 1996, 35, 613-616.	2.9	16
556	Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1996, 71, 173-177.	2.3	106
557	A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18.. Journal of Clinical Investigation, 1996, 97, 1155-1164.	8.2	87
558	CLONING AND EXPRESSION OF HUMAN S-LAMININ. Biochemical Society Transactions, 1996, 24, 278S-278S.	3.4	0

#	Article	IF	Citations
559	Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Current Opinion in Immunology, 1996, 8, 865-871.	5.5	33
560	A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology, 1996, 47, 1552-1555.	1.1	71
561	Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function.. Journal of Clinical Investigation, 1996, 98, 2358-2363.	8.2	146
562	Acquired neuromyotonia: Evidence for autoantibodies directed against K⁺channels of peripheral nerves. Annals of Neurology, 1995, 38, 714-722.	5.3	414
563	Differences in processing of an autoantigen by DR4:Dw4.2 and DR4:Dw14.2 antigen-presenting cells. European Journal of Immunology, 1995, 25, 2119-2122.	2.9	10
564	Autoantibodies, neurotoxins and the nervous system. Journal of Physiology (Paris), 1995, 89, 129-136.	2.1	17
565	An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 85-87.	1.9	232
566	Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells. Journal of Neuroimmunology, 1995, 56, 65-76.	2.3	51
567	Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet, The, 1995, 346, 24-25.	13.7	156
568	Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis. Journal of Immunology, 1995, 154, 6382-96.	0.8	12
569	Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. Journal of Immunology, 1995, 155, 3683-92.	0.8	42
570	Amyotrophic lateral sclerosis. An autoimmune disease?. Advances in Neurology, 1995, 68, 59-65.	0.8	17
571	Immunogenicity of Human Recombinant Acetylcholine Receptor Î± Subunit: Cytoplasmic Epitopes Dominate the Antibody Response in four Mouse Strains. Autoimmunity, 1994, 18, 113-119.	2.6	9
572	Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line. Pflugers Archiv European Journal of Physiology, 1994, 428, 492-498.	2.8	27
573	Passive transfer of seronegative myasthenia gravis to mice. Muscle and Nerve, 1994, 17, 1393-1400.	2.2	95
574	Response to human acetylcholine receptor Î±138â€“199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunology Letters, 1994, 39, 269-275.	2.5	36
575	Letter to the editor. Journal of Neuroimmunology, 1994, 53, 115.	2.3	1
576	Molecular characterisation of the human muscle nicotinic acetylcholine receptor genes. Neuromuscular Disorders, 1994, 4, S50.	0.6	0

#	Article	IF	Citations
577	Aetiological factors in development of myasthenia gravis. Advances in Neuroimmunology, 1994, 4, 355-371.	1.8	38
578	Is the AChR Î±373â€“380 sequence a T or B cell epitope in thymoma associated-myasthenia gravis?. Neuromuscular Disorders, 1994, 4, S34.	0.6	1
579	Fetal acetylcholine receptor function reduced by serum from asymptomatic mother with history of fetal arthrogryposis. Neuromuscular Disorders, 1994, 4, S19.	0.6	0
580	Single channel properties of human muscle nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes. Neuromuscular Disorders, 1994, 4, S47.	0.6	0
581	Autoantibodies to voltage-gated potassium channels in acquired neuromyotonia. Neuromuscular Disorders, 1994, 4, S28.	0.6	4
582	â€œSpreadingâ€•of B cell determinants in experimental myasthenia gravis induced by acetylcholine receptor peptides. Neuromuscular Disorders, 1994, 4, S45.	0.6	0
583	Lambert-Eaton myasthenic syndrome IgG identifies calcium channel subtypes in neuronal cell lines. Neuromuscular Disorders, 1994, 4, S11.	0.6	0
584	Thymoma epithelial cells can present AChR antigens to specific T cells. Neuromuscular Disorders, 1994, 4, S31.	0.6	0
585	Involvement of cation channels in autoimmune disease. Biochemical Society Transactions, 1994, 22, 488-491.	3.4	1
586	Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes.. Journal of Clinical Investigation, 1994, 93, 1361-1369.	8.2	74
587	Pathogenic autoimmunity to affinity-purified mouse acetylcholine receptor induced without adjuvant in BALB/c mice. European Journal of Immunology, 1993, 23, 973-976.	2.9	47
588	Primary structure of the human muscle acetylcholine receptor. cDNA cloning of the gamma and e subunits. FEBS Journal, 1993, 215, 229-238.	0.2	70
589	Congenital Myasthenic Syndromes. Neuromuscular Disorders, 1993, 3, 183-190.	0.6	30
590	Presentation of endogenous acetylcholine receptor epitope by an MHC class II-transfected human muscle cell line to a specific CD4+ T cell clone from a myasthenia gravis patient. Journal of Neuroimmunology, 1993, 46, 57-65.	2.3	29
591	cDNA and Genomic Clones Encoding the Human Muscle Acetylcholine Receptor. Annals of the New York Academy of Sciences, 1993, 681, 165-167.	3.8	8
592	Approaches for Studying the Pathogenic T Cells in Autoimmune Patients. Annals of the New York Academy of Sciences, 1993, 681, 219-237.	3.8	33
593	HL A-A2-Restricted T-Cell Line Recognizing an Epitope of the Human Acetylcholine Receptor. Annals of the New York Academy of Sciences, 1993, 681, 276-279.	3.8	2
594	Stimulation of Specific T Cells by Human A ChR Adsorbed to Immunomagnetic Particles. Annals of the New York Academy of Sciences, 1993, 681, 288-291.	3.8	0

#	Article	IF	Citations
595	EAMG Induced in Rabbits by Immunization against Peptides Representing Human AChR ?138?199. Annals of the New York Academy of Sciences, 1993, 681, 295-297.	3.8	4
596	Clinical and Experimental Observations in Patients with Congenital Myasthenic Syndromes. Annals of the New York Academy of Sciences, 1993, 681, 451-460.	3.8	27
597	Seronegative Myasthenia Gravis: Evidence for Plasma Factor(s) Interfering with Acetylcholine Receptor Function. Annals of the New York Academy of Sciences, 1993, 681, 529-538.	3.8	63
598	An in Vitro Model for Disease-specific Immunotherapy in Myasthenia Gravis Using Soluble MHC Class II Bound to AChR-derived Peptide. Annals of the New York Academy of Sciences, 1993, 681, 577-580.	3.8	1
599	Human nicotinic acetylcholine receptor Î±-subunit isoforms: origins and expression. Nucleic Acids Research, 1993, 21, 5463-5467.	14.5	24
600	Role of acetylcholine receptor antibody complexes in muscle in experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1992, 36, 117-125.	2.3	17
601	Stimulation of human T cells by sparse antigens captured on immunomagnetic particles. Journal of Immunological Methods, 1992, 155, 41-48.	1.4	22
602	Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet, The, 1991, 338, 75-77.	13.7	228
603	Antibody-mediated neurological disease. Current Opinion in Neurobiology, 1991, 1, 430-435.	4.2	4
604	Role of acetylcholine receptor antibody complexes in experimental autoimmune myasthenia gravis. Journal of Autoimmunity, 1991, 4, xxviii.	6.5	0
605	Fine specificity of an AChR-reactive T cell line from a young myasthenic patient. Journal of Autoimmunity, 1991, 4, xi.	6.5	0
606	Two isoforms of the muscle acetylcholine receptor Î±-subunit are translated in the human cell line TE671. FEBS Letters, 1991, 295, 116-118.	2.8	29
607	Acquired neuromyotonia (Isaac's syndrome): Evidence for an antibody-mediated mechanism. Journal of Neuroimmunology, 1991, 35, 68.	2.3	0
608	Binding of acetylcholine receptor Î±-subunit peptides to HLA-A2. Journal of Neuroimmunology, 1991, 35, 115.	2.3	0
609	Selecting T cell lines in myasthenia gravis (MG) using recombinant human autoantigen. Journal of Neuroimmunology, 1991, 35, 116.	2.3	0
610	Lectins affect ACHR function in TE671 cells: A possible model for seronegative MG plasma. Journal of Neuroimmunology, 1991, 35, 194.	2.3	0
611	Autoimmunity to acetylcholine receptors in myasthenia gravis. Biochemical Society Transactions, 1991, 19, 180-183.	3.4	10
612	Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7343-7347.	7.1	93

#	Article	IF	Citations
613	BOOK REVIWES. Brain, 1990, 113, 1920-1921.	7.6	0
614	Î±-Neurotoxin binding to the human nicotinic acetylcholine receptor. Biochemical Society Transactions, 1990, 18, 889-890.	3.4	2
615	A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle and Nerve, 1990, 13, 407-413.	2.2	44
616	The human muscle nicotinic acetylcholine receptor alpha-subunit exist as two isoforms: a novel exon. EMBO Journal, 1990, 9, 2101-6.	7.8	30
617	Plasma from anti-AChR Ab negative MG patients reduces Na+ influx into TE671 cells. Journal of Autoimmunity, 1989, 2, 930.	6.5	0
618	T-Cell epitopes in patients with myasthenia gravis defined by the use of recombinant polypeptides of the humanacetylcholine receptor. Journal of Autoimmunity, 1989, 2, 903.	6.5	1
619	Mouse T and B cell recognition epitopes on the recombinant human muscle acetylcholine receptor Î±-subunit. Journal of Autoimmunity, 1989, 2, 905.	6.5	0
620	Motor Nerve Terminal Calcium Channels in Lambert-Eaton Myasthenic Syndrome.. Annals of the New York Academy of Sciences, 1989, 560, 278-290.	3.8	21
621	K+-Stimulated Ca2+Influx in Cell Lines Derived from Small Cell Lung Cancer and Neuronal Tumors. Annals of the New York Academy of Sciences, 1989, 560, 294-296.	3.8	5
622	Isolation and expression of cDNAS for the human muscle nicotinic acetylcholine receptor. Journal of Autoimmunity, 1989, 2, 902.	6.5	0
623	Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends in Neurosciences, 1989, 12, 496-502.	8.6	165
624	Human muscle acetylcholine receptor: cloning and expression in Escherichia coli of cDNA for the Î±-subunit. Biochemical Society Transactions, 1989, 17, 219-220.	3.4	25
625	Epitopes on human acetylcholine receptor Î±-subunit: binding of monoclonal antibodies to recombinant and synthetic peptides. Biochemical Society Transactions, 1989, 17, 220-221.	3.4	15
626	Lambert-Eaton syndrome antibodies: reaction with membranes from a small cell lung cancer xenograft. Journal of Neuroimmunology, 1988, 18, 97-104.	2.3	17
627	Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect. Journal of the Neurological Sciences, 1988, 84, 15-28.	0.6	36
628	Expression of Voltage-Gated Calcium Channels in Tumor Cell Lines of Neuroectodermal or Other Origin. Annals of the New York Academy of Sciences, 1988, 540, 389-391.	3.8	2
629	Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line. Journal of Neuroimmunology, 1988, 19, 141-148.	2.3	48
630	Immunological and pharmacological heterogeneity of Î±-bungarotoxin binding sites extracted from TE671 cells. Journal of Neuroimmunology, 1988, 19, 149-157.	2.3	26

#	Article	IF	Citations
631	Epitopes on Human Acetylcholine Receptor Defined by Monoclonal Antibodies and Myasthenia Gravis Sera. Autoimmunity, 1988, 1, 285-297.	2.6	42
632	Monoclonal Anti-Acetycholine Receptor Antibodies as Probes for Human Acetylcholine-Receptor in Myasthenia Gravis. Journal of Receptors and Signal Transduction, 1988, 8, 143-159.	1.2	1
633	Neuroimmunology of myasthenia gravis. Brain, Behavior, and Immunity, 1988, 2, 346-351.	4.1	6
634	Differences in Fine Specificity of Anti-Acetylcholine Receptor Antibodies between Subgroups of Spontaneous Myasthenia Gravis of Recent Onset, and of Penicillamine Induced Myasthenia. Autoimmunity, 1988, 2, 31-37.	2.6	13
635	Action of antibodies directed against the acetylcholine receptor on channel function at mouse and rat motor end-plates.. Journal of Physiology, 1988, 399, 577-589.	2.9	4
636	Antiâ€acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology, 1988, 38, 1784-1784.	1.1	32
637	Antibody specificity in myasthenia gravis. Monographs in Allergy, 1988, 25, 33-40.	0.2	7
638	Disorders Affecting the Acetylcholine Receptor: Myasthenia Gravis and Congenital Myasthenia. Journal of Receptors and Signal Transduction, 1987, 7, 599-616.	1.2	6
639	Expression of voltage-gated calcium channels in tumour cell lines of neuroectodermal or other origin. Journal of Neuroimmunology, 1987, 16, 101-102.	2.3	0
640	Epitopes on human ACHR defined by monoclonal antibodies. Journal of Neuroimmunology, 1987, 16, 178-179.	2.3	0
641	Immunological Heterogeneity and Cellular Mechanisms in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1987, 505, 12-26.	3.8	58
642	Antibody Heterogeneity and Specificity in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1987, 505, 106-120.	3.8	72
643	Lambert-Eaton Myasthenic Syndrome IgG: Early Morphologic Effects and Immunolocalization at the Motor Endplate. Annals of the New York Academy of Sciences, 1987, 505, 333-345.	3.8	17
644	Development of an Adjuvant-Independent Model of Myasthenia Gravis in Mice. Annals of the New York Academy of Sciences, 1987, 505, 806-808.	3.8	1
645	Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study. Annals of Neurology, 1987, 22, 212-222.	5.3	229
646	MYASTHENIA GRAVIS WITHOUT ACETYLCHOLINE-RECEPTOR ANTIBODY: A DISTINCT DISEASE ENTITY. Lancet, The, 1986, 327, 116-119.	13.7	202
647	Monoclonal antibodies that distinguish between normal and denervated human acetylcholine re receptor. Journal of Neuroimmunology, 1986, 11, 223-235.	2.3	53
648	Myasthenia gravis. Neurology, 1986, 36, 612-612.	1.1	46

#	Article	IF	Citations
649	Anti-acetylcholine receptor antibodies induced in mice by syngeneic receptor without adjuvants. Immunology, 1986, 58, 151-5.	4.4	13
650	Monoclonal antibodies to the human acetylcholine receptor. Biochemical Society Transactions, 1985, 13, 116-117.	3.4	1
651	Monoclonal antibodies to the Î±-bungarotoxin-binding site on acetylcholine receptors from Torpedo mamorata. Biochemical Society Transactions, 1985, 13, 117-118.	3.4	1
652	Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature, 1985, 317, 737-739.	27.8	253
653	Monoclonal antibodies to Torpedo acetylcholine receptor. Characterisation of antigenic determinants within the cholinergic binding site. FEBS Journal, 1985, 150, 533-539.	0.2	36
654	Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.. Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 1246-1252.	1.9	422
655	Acetylcholine receptor antibodies in the elderly and in Down's syndrome. Journal of Neuroimmunology, 1985, 9, 139-146.	2.3	13
656	Anti-acetylcholine receptor idiotypes in myasthenia gravis analysed by rabbit anti-sera. Clinical and Experimental Immunology, 1985, 60, 637-44.	2.6	21
657	Acetylcholine receptor antibody characteristics in myasthenia gravis. III. Patients with low anti-AChR antibody levels. Clinical and Experimental Immunology, 1985, 60, 631-6.	2.6	23
658	Passive Transfer of Lambert-Eaton Myasthenic Syndrome in Mice: Decreased Rates of Resting and Evoked Release of Acetylcholine from Skeletal Muscle. Journal of Neurochemistry, 1984, 42, 658-662.	3.9	31
659	4 Acetylcholine receptors and myasthenia gravis. Clinics in Endocrinology and Metabolism, 1983, 12, 57-78.	1.6	6
660	Acetycholine receptor antibody characteristics in myasthenia gravisâ˜†Fractionation of Î±-Bungarotoxin binding site antibodies and their relationship to IgG subclass. Journal of Neuroimmunology, 1983, 5, 1-9.	2.3	31
661	Immunological aspects of acetycholine receptors. Trends in Neurosciences, 1983, 6, 249-251.	8.6	4
662	Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis.. Journal of Neurology, Neurosurgery and Psychiatry, 1983, 46, 383-387.	1.9	28
663	Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 7636-7640.	7.1	286
664	Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology, 1983, 33, 1276-1276.	1.1	86
665	Anti-acetylcholine receptor antibody: Use of polyethylene glycol as an aid to precipitation of antibody-receptor complexes in determination of light chain and subclass. Journal of Immunological Methods, 1982, 51, 359-369.	1.4	11
666	Purification of anti-acetylcholine receptor antibody from patients with myasthenia gravis. Journal of Immunological Methods, 1982, 51, 371-381.	1.4	21

#	Article	IF	Citations
667	Acetylcholine Receptor Antibody: Clinical and Experimental Aspects. Novartis Foundation Symposium, 1982, , 225-247.	1.1	9
668	Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset. Clinical and Experimental Immunology, 1982, 49, 266-72.	2.6	39
669	Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clinical and Experimental Immunology, 1982, 49, 257-65.	2.6	136
670	Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle and Nerve, 1982, 5, S17-20.	2.2	33
671	ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY SYNTHESIS BY CULTURED LYMPHOCYTES IN MY ASTHENIA GRAVIS: THYMIC AND PERIPHERAL BLOOD CELL INTERACTIONS. Annals of the New York Academy of Sciences, 1981, 377, 393-402.	3.8	31
672	ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY HETEROGENEITY IN DIFFERENT FORMS OF MYASTHENIA GRAVIS. Annals of the New York Academy of Sciences, 1981, 377, 895-897.	3.8	0
673	AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROME. Lancet, The, 1981, 318, 224-226.	13.7	337
674	Congenital myasthenia: End-plate acetylcholine receptors and electrophysiology in five cases. Muscle and Nerve, 1981, 4, 306-318.	2.2	119
675	Idiotype restriction in myasthenia gravis antibodies. Nature, 1981, 290, 293-294.	27.8	17
676	Choline Acetyltransferase in Skeletal Muscle from Patients with Myasthenia Gravis. Journal of Neurochemistry, 1981, 37, 1081-1088.	3.9	25
677	Acetylcholine receptor antibody synthesis by thymic lymphocytes. Neurology, 1981, 31, 935-935.	1.1	170
678	Absence of anti-acetylcholine receptor antibodies in Praomys (Mastomys) natalensis. Clinical and Experimental Immunology, 1981, 43, 94-8.	2.6	5
679	Immunology of acetylcholine receptors in relation to myasthenia gravis.. Physiological Reviews, 1980, 60, 756-824.	28.8	255
680	Anti-acetylcholine receptor antibodies.. Journal of Neurology, Neurosurgery and Psychiatry, 1980, 43, 590-600.	1.9	142
681	CLINICAL, PATHOLOGICAL, HLA ANTIGEN AND IMMUNOLOGICAL EVIDENCE FOR DISEASE HETEROGENEITY IN MYASTHENIA GRAVIS. Brain, 1980, 103, 579-601.	7.6	463
682	Tissue-specific antibodies in myasthenia gravis.. Journal of Clinical Pathology, 1979, s3-13, 97-106.	2.0	4
683	Acetylcholine in Intercostal Muscle from Myasthenia Gravis Patients and in Rat Diaphragm after Blockade of Acetylcholine Receptors. Progress in Brain Research, 1979, 49, 449-458.	1.4	38
684	alpha-Bungarotoxin and anti-acetylcholine receptor antibody binding to the human acetylcholine receptor. Advances in Cytopharmacology, 1979, 3, 269-78.	0.3	16

#	Article	IF	Citations
685	IN-VITRO SYNTHESIS OF ANTI-ACETYLCHOLINE-RECEPTOR ANTIBODY BY THYMIC LYMPHOCYTES IN MYASTHENIA GRAVIS. Lancet, The, 1978, 311, 305-307.	13.7	134
686	ACETYLCHOLINE RECEPTORS AND END-PLATE ELECTROPHYSIOLOGY IN MYASTHENIA GRAVIS. Brain, 1978, 101, 345-368.	7.6	115
687	Function of circulating antibody to acetylcholine receptor in myasthenia gravis. Neurology, 1978, 28, 266-266.	1.1	258
688	[Plasmapheresis for myasthenia gravis]. New England Journal of Medicine, 1978, 298, 456-7.	27.0	11
689	Myasthenia gravis â€" latest developments. Trends in Biochemical Sciences, 1977, 2, N275-N276.	7.5	0
690	Acetylcholine in human muscle. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1976, 192, 475-480.	1.8	30
691	Experimental myasthenia gravis â€" a new autoimmune model. Trends in Biochemical Sciences, 1976, 1, 289-291.	7.5	0
692	New support for autoimmune basis of myasthenia gravis. Nature, 1975, 256, 10-11.	27.8	1
693	Neuromuscular transmission after immunization against acetylcholine receptors. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1975, 189, 57-68.	1.8	63
694	Acetylcholine receptors. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences, 1975, 270, 551-559.	2.3	41
695	Use of Anti-Nerve Antibodies. , 0, , 87-93.		0